JD induced pluripotent stem cell–derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia

Elevated levels of low‐density lipoprotein cholesterol (LDL‐C) in plasma are a major contributor to cardiovascular disease, which is the leading cause of death worldwide. Genome‐wide association studies (GWAS) have identified 95 loci that associate with control of lipid/cholesterol metabolism. Although GWAS results are highly provocative, direct analyses of the contribution of specific allelic variations in regulating LDL‐C has been challenging due to the difficulty in accessing appropriate cells from affected patients. The primary cell type responsible for controlling cholesterol and lipid flux is the hepatocyte. Recently, we have shown that cells with hepatocyte characteristics can be generated from human induced pluripotent stem cells (iPSCs). This finding raises the possibility of using patient‐specific iPSC‐derived hepatocytes to study the functional contribution of GWAS loci in regulating lipid metabolism. To test the validity of this approach, we produced iPSCs from JD a patient with mutations in the low‐density lipoprotein receptor (LDLR) gene that result in familial hypercholesterolemia (FH). We demonstrate that (1) hepatocytes can be efficiently generated from FH iPSCs; (2) in contrast to control cells, FH iPSC‐derived hepatocytes are deficient in LDL‐C uptake; (3) control but not FH iPSC‐derived hepatocytes increase LDL uptake in response to lovastatin; and (4) FH iPSC‐derived hepatocytes display a marked elevation in secretion of lipidated apolipoprotein B‐100. Conclusion: Cumulatively, these findings demonstrate that FH iPSC‐derived hepatocytes recapitulate the complex pathophysiology of FH in culture. These results also establish that patient‐specific iPSC‐derived hepatocytes could be used to definitively determine the functional contribution of allelic variation in regulating lipid and cholesterol metabolism and could potentially provide a platform for the identification of novel treatments of cardiovascular disease. (HEPATOLOGY 2012)

[1]  M. Brown,et al.  Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. , 1999, The Journal of clinical investigation.

[2]  D. Rader,et al.  Normal Production Rate of Apolipoprotein B in LDL Receptor–Deficient Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[3]  Yoav Mayshar,et al.  Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. , 2010, Cell stem cell.

[4]  D. Rader,et al.  Complete Deficiency of the Low-Density Lipoprotein Receptor Is Associated With Increased Apolipoprotein B-100 Production , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[5]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[6]  Richard G. W. Anderson,et al.  The J. D. mutation in familial hypercholesterolemia: Amino acid substitution in cytoplasmic domain impedes internalization of LDL receptors , 1986, Cell.

[7]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[8]  George Q. Daley,et al.  Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.

[9]  Martin J. Aryee,et al.  Epigenetic memory in induced pluripotent stem cells , 2010, Nature.

[10]  Jehyuk Lee,et al.  Generation of functional human hepatic endoderm from human induced pluripotent stem cells , 2009, Hepatology.

[11]  Rudolf Jaenisch,et al.  Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.

[12]  J. Roy-Chowdhury,et al.  Modeling and therapy of human liver diseases using induced pluripotent stem cells: How far have we come? , 2011, Hepatology.

[13]  B. Lamarche,et al.  Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation Published, JLR Papers in Press, February 16, 2004. DOI 10.1194/jlr.M300448-JLR200 , 2004, Journal of Lipid Research.

[14]  E. Kirkness,et al.  Somatic coding mutations in human induced pluripotent stem cells , 2011, Nature.

[15]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[16]  Andrew P. Feinberg,et al.  Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells , 2011, Nature Biotechnology.

[17]  Ludovic Vallier,et al.  Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. , 2010, The Journal of clinical investigation.

[18]  G. Konopka,et al.  HNF4A is essential for specification of hepatic progenitors from human pluripotent stem cells , 2011, Journal of Cell Science.

[19]  G. Watts,et al.  Role of cholesterol in regulating apolipoprotein B secretion by the liver. , 1996, Journal of lipid research.

[20]  J. Goldstein,et al.  The LDL receptor. , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[21]  A. Attie,et al.  The role of the LDL receptor in apolipoprotein B secretion. , 2000, The Journal of clinical investigation.

[22]  R. Havel,et al.  Secretion of lipoproteins from the liver of normal and Watanabe heritable hyperlipidemic rabbits. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[23]  A. Bradley,et al.  Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells , 2011, Nature.

[24]  G. Watts,et al.  Regulation of plasma LDL: the apoB paradigm , 2009, Clinical science.

[25]  G. Ginsburg,et al.  The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.

[26]  James A. Thomson,et al.  Induced pluripotent stem cells from a spinal muscular atrophy patient , 2009, Nature.

[27]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[28]  T. Mikkelsen,et al.  Dissecting direct reprogramming through integrative genomic analysis , 2008, Nature.

[29]  G. Ginsburg,et al.  Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response , 2008, Circulation. Cardiovascular genetics.

[30]  Stephen Dalton,et al.  Highly efficient generation of human hepatocyte–like cells from induced pluripotent stem cells , 2010, Hepatology.

[31]  K. Furie,et al.  Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2008, Circulation.

[32]  Xiaolei Yin,et al.  Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells , 2009, Cell Research.

[33]  R. Stewart,et al.  Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.